OCUL / Ocular Therapeutix, Inc. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

Employment Agreement, by and between the Registrant and Namrata Saroj, dated November 3, 2024

Exhibit 10.5 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is made as of November 3, 2024, by and between Ocular Therapeutix, Inc., a Delaware corporation (the “Company”), and Namrata Saroj (“Executive”). This Agreement supersedes all prior agreements or exchanges between the parties and is intended to set forth the terms of Executive’s employment as of November 4, 2024 (the “Co

Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights Outstanding patient retention and clinical execution in complementary AXPAXLI™ SOL trials for wet AMD SOL-1 remains on track for 1Q 2026 topline data SOL-R resc

Exhibit 99.1 Ocular Therapeutix™ Reports Second Quarter 2025 Financial Results and Business Highlights Outstanding patient retention and clinical execution in complementary AXPAXLI™ SOL trials for wet AMD SOL-1 remains on track for 1Q 2026 topline data SOL-R rescue criteria streamlined and simplified with topline data expected in 1H 2027 Planning to incorporate single long-term extension study for

Employment Agreement, by and between the Registrant and Steve Meyers, dated January 27, 2023

Exhibit 10.3 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) amends and restates the terms and conditions of your employment with Ocular Therapeutix, Inc., as set forth in your Employment Agreement dated February 17, 2022 (the “Existing Employment Agreement”) and will be effective as of January 27th, 2023 (the “Effective Date”), provided that you remain employed by the Company as

2021 Stock Incentive Plan, as amended

Exhibit 10.1 Ocular Therapeutix, Inc. 2021 STOCK INCENTIVE PLAN, AS AMENDED 1. Purpose The purpose of this 2021 Stock Incentive Plan (the “Plan”) of Ocular Therapeutix, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00

Certificate of Amendment of Restated Certificate of Incorporation, as amended

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF Ocular therapeutix, Inc. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Ocular Therapeutix, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware, does hereby certify as follows: A

First Amendment to Employment Agreement, by and between the Registrant and Steve Meyers, dated August 3, 2023

Exhibit 10.4 Ocular Therapeutix Draft of 7/26/23 AMENDMENT #1 TO EMPLOYMENT AGREEMENT This First Amendment (the “First Amendment”) to the Agreement (as defined below) is dated as of August 3, 2023 (the “Effective Date”), and entered into by and between Ocular Therapeutix, Inc., with offices at 24 Crosby Drive, Bedford, MA 01730 (hereinafter referred to as “Ocular”) and Steve Meyers with offices at

Amended and Restated 2014 Employee Stock Purchase Plan

Exhibit 10.2 OCULAR THERAPEUTIX, INC. AMENDED AND RESTATED 2014 EMPLOYEE STOCK PURCHASE PLAN This Amended and Restated 2014 Employee Stock Purchase Plan (this “Plan”) of Ocular Therapeutix, Inc. (the “Company”) amends and restates the Company’s 2014 Employee Stock Purchase Plan in its entirety. The purpose of the Plan is to provide eligible employees of the Company and certain of its subsidiaries

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 OCULAR THERAPEUTIX

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File N

Certificate of Amendment of Restated Certificate of Incorporation, as amended, of Ocular Therapeutix, Inc.

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF Ocular therapeutix, Inc. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Ocular Therapeutix, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware, does hereby certify as follows: A

Filing Fee Table

Calculation of Filing Fee Tables S-8 OCULAR THERAPEUTIX, INC Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 OCULAR THERAPEUTIX,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 OCULAR THERAPEUTIX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission

Restated Certificate of Incorporation of the Registrant, as amended

Exhibit 4.1 RESTATED CERTIFICATE OF INCORPORATION OF OCULAR THERAPEUTIX, INC. (originally incorporated on September 12, 2006) Ocular Therapeutix, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows: A. The current name of the Corpo

As filed with the Securities and Exchange Commission on June 11, 2025

As filed with the Securities and Exchange Commission on June 11, 2025 Registration No.

Performance Stock Unit Agreement by and between the Registrant and Dr. Pravin U. Dugel, dated as of February 11, 2025

Exhibit 10.4 OCULAR THERAPEUTIX, INC. PERFORMANCE STOCK UNIT AGREEMENT Ocular Therapeutix, Inc. (the “Company”) hereby grants the following performance stock units pursuant to its 2021 Stock Incentive Plan, as amended. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the “Participant”): Dr. Pravin Dugel Grant Date: February 11, 2025 Number of perf

Restricted Stock Unit Agreement by and between the Registrant and Dr. Pravin U. Dugel, dated as of February 11, 2025

EX-10.3 2 ocul-20250331xex10d3.htm EX-10.3 Exhibit 10.3 OCULAR THERAPEUTIX, INC. RESTRICTED STOCK UNIT AGREEMENT Ocular Therapeutix, Inc. (the “Company”) hereby grants the following restricted stock units pursuant to its 2021 Stock Incentive Plan, as amended. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the “Participant”): Dr. Pravin Dugel Gra

Performance Stock Option Agreement by and between the Registrant and Dr. Pravin U. Dugel, dated as of February 11, 2025

EX-10.5 4 ocul-20250331xex10d5.htm EX-10.5 Exhibit 10.5 OCULAR THERAPEUTIX, INC. PERFORMANCE STOCK OPTION AGREEMENT Ocular Therapeutix, Inc. (the “Company”) hereby grants the following stock option (this “Option”) pursuant to its 2021 Stock Incentive Plan, as amended. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the “Participant”): Dr. Pravin D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 OCULAR THERAPEUTIX, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2025 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights AXPAXLI™ SOL trials for wet AMD progressing rapidly following recent updates to accelerate and enhance the registrational program Following positive FDA feedback for poten

Exhibit 99.1 Ocular Therapeutix™ Reports First Quarter 2025 Results and Business Highlights AXPAXLI™ SOL trials for wet AMD progressing rapidly following recent updates to accelerate and enhance the registrational program Following positive FDA feedback for potential AXPAXLI NPDR registrational trial, Ocular is actively planning next steps in NPDR and DME SOL-1 retention remains exceptional as tri

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36554

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 OCULAR THERAPEUTIX,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Subsidiaries of the Registrant

EX-21.1 5 ocul-20241231xex21d1.htm EX-21.1 Exhibit 21.1 Subsidiaries of Ocular Therapeutix, Inc. Jurisdiction of Incorporation or Organization Ocular Therapeutix Europe B.V. The Netherlands Ocular Therapeutix Securities Corp. The Commonwealth of Massachusetts

Amendment No. 2 to the Employment Agreement by and between the Registrant and Dr. Peter Kaiser, dated as of March 1, 2025

Exhibit 10.52 Ocular Therapeutix, Inc. 15 Crosby Drive Bedford, MA 01730 March 1, 2025 Peter K. Kaiser, MD Ocular Therapeutix, Inc. RE:Second Amendment to Employment Agreement Dear Peter, This letter agreement (the “Second Amendment”) amends that certain Employment Agreement, dated as of February 21, 2024, and amended in a letter agreement dated March 28, 2024 (as amended to date, the “Employment

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights Announces several updates to enhance and accelerate AXPAXLI registrational program in wet AMD, potentially supporting label flexibility of 6-12 months to sh

Exhibit 99.1 Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights Announces several updates to enhance and accelerate AXPAXLI registrational program in wet AMD, potentially supporting label flexibility of 6-12 months to showcase expected best-in-class durability FDA approves Amendment to SOL-1 Special Protocol Agreement (SPA) to include AXPAXLI re-dosing at

Amendment No. 1 to the Employment Agreement by and between the Registrant and Dr. Jeffrey Heier, dated as of March 1, 2025

Exhibit 10.49 Ocular Therapeutix, Inc. 15 Crosby Drive Bedford, MA 01730 March 1, 2025 Jeffrey Heier, MD Ocular Therapeutix, Inc. RE:First Amendment to Employment Agreement Dear Jeff, This letter agreement (the “First Amendment”) amends that certain Employment Agreement, dated as of February 21, 2024 (the “Employment Agreement”) by and between you and Ocular Therapeutix, Inc. (the “Company”). 1.Se

Insider Trading Policies and Procedures

Exhibit 19.1 OCULAR THERAPEUTIX, INC. Insider Trading Policy 1. Background and purpose The federal securities laws prohibit any member of the Board of Directors (a “Director”) or employee of Ocular Therapeutix, Inc. (together with its subsidiaries, the “Company”) from purchasing or selling Company securities on the basis of material nonpublic information concerning the Company, or from tipping mat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2025 OCULAR THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2025 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission Fil

Amendment No. 1 to the Employment Agreement by and between the Registrant and Dr. Peter Kaiser, dated as of March 28, 2024

Exhibit 10.3 Ocular Therapeutix, Inc. 15 Crosby Drive Bedford, MA 01730 March 28, 2024 Peter K. Kaiser, MD Ocular Therapeutix, Inc. Medical Director Dear Peter: Section 1(b) of the employment agreement dated as of February 21, 2024 (the “Employment Agreement”) between you and Ocular Therapeutix, Inc. (the “Company”) provides that you will be employed by the Company to serve on a part-time basis, w

Employment Agreement by and between the Registrant and Dr. Peter Kaiser, dated as of February 21, 2024

Exhibit 10.2 Execution Version EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) sets forth the terms and conditions of your employment with Ocular Therapeutix, Inc., and will be effective as of February 21, 2024 (the “Effective Date”). Until the Effective Date, the Healthcare Professional Consulting Agreement, dated June 1, 2022, by and between the Company and Peter K. Kaiser, MD (

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Ocular Therapeutix, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission Fil

Employment Agreement by and between the Registrant and Todd Anderman, dated as of October 4, 2024

Exhibit 10.4 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is made as of October 4, 2024, by and between Ocular Therapeutix, Inc., a Delaware corporation (the “Company”), and Todd D.C. Anderman (“Executive”). This Agreement supersedes all prior agreements or exchanges between the parties and sets forth the terms of Executive’s employment as of October 7, 2024 (the “Commencement

OCUL / Ocular Therapeutix, Inc. / Venrock Healthcare Capital Partners III, L.P. - SC 13G/A Passive Investment

SC 13G/A 1 tm2428137d12sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Ocular Therapeutix, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 67576A100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this State

As filed with the Securities and Exchange Commission on November 14, 2024

As filed with the Securities and Exchange Commission on November 14, 2024 Registration No.

Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Active clinical trial sites now enrolling patients directly into SOL-R Cash balance

Exhibit 99.1 Ocular Therapeutix™ Reports Third Quarter 2024 Results and Business Highlights SOL-1 expected to be fully randomized by YE 2024 with topline data expected in Q4 2025 Active clinical trial sites now enrolling patients directly into SOL-R Cash balance of $427.2M as of September 30, 2024, expected to fund operations into 2028 Ocular to host a Q3 2024 conference call and webcast today, No

JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)

EXHIBIT 1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

OCUL / Ocular Therapeutix, Inc. / Avoro Capital Advisors LLC - OCULAR THERAPEUTIX, INC. Passive Investment

SC 13G 1 p24-3167sc13g.htm OCULAR THERAPEUTIX, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Ocular Therapeutix, Inc (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 67576A100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Che

Employment Agreement by and between the Registrant and Dr. Jeffrey Heier, dated as of February 21, 2024

Exhibit 10.1 Execution Version EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) sets forth the terms and conditions of your employment with Ocular Therapeutix, Inc., and will be effective as of February 21, 2024 (the “Effective Date”). Until the Effective Date, the Healthcare Professional Consulting Agreement, dated June 1, 2022, by and between the Company and Jeffrey Heier, MD (th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2024 OCULAR THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2024 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File

OCULAR THERAPEUTIX, INC. Amendment No. 4 to 2019 Inducement Stock Incentive Plan

Exhibit 99.1 OCULAR THERAPEUTIX, INC. Amendment No. 4 to 2019 Inducement Stock Incentive Plan Ocular Therapeutix, Inc’s 2019 Inducement Stock Incentive Plan (the “Plan”), pursuant to Section 11(d) thereof, is hereby amended as set forth below. 1. The first sentence of Section 4(a) of the Plan be, and hereby is, deleted in its entirety and replaced with the following in lieu thereof: “Subject to ad

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2024 OCULAR THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2024 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File N

Separation Agreement by and between the Registrant and Antony C. Mattessich, dated May 1, 2024

Exhibit 10.3 Execution Version VIA ELECTRONIC MAIL May 1, 2024 Antony C. Mattessich 82 Lenox Street Newton, MA 02465 Dear Antony: As we discussed, your employment with Ocular Therapeutics, Inc. (the “Company”) will end effective May 2, 2024 (the “Separation Date”). In connection with the termination of your employment, you will be eligible to receive the severance benefits described in paragraph 1

Ocular Therapeutix™ Reports Second Quarter 2024 Results SOL-R AXPAXLI™ Repeat Dosing Study in Wet AMD Acceptable to FDA as Registrational Trial Enrollment in SOL-1 Continues to Accelerate and SOL-R Actively Enrolling Patients Cash Balance of $459.7M

Exhibit 99.1 Ocular Therapeutix™ Reports Second Quarter 2024 Results SOL-R AXPAXLI™ Repeat Dosing Study in Wet AMD Acceptable to FDA as Registrational Trial Enrollment in SOL-1 Continues to Accelerate and SOL-R Actively Enrolling Patients Cash Balance of $459.7M as of June 30, 2024, Expected to Fund Operations into 2028 Ocular Will Host a Q2 2024 Conference Call and Webcast Today, August 7th, at 8

Employment Agreement by and between the Registrant and Nadia Waheed, dated April 15, 2024

Exhibit 10.5 EXECUTION COPY EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is made as of April 15, 2024, by and between Ocular Therapeutix, Inc., a Delaware corporation (the “Company”), and Nadia Waheed (“Executive”). This Agreement supersedes all prior agreements or exchanges between the parties and is intended to set forth the terms of Executive’s employment as of May 20, 2024

Letter Agreement by and between the Registrant and Nadia Waheed, dated April 22, 2024

Exhibit 10.6 Ocular Therapeutix, Inc. 15 Crosby Drive Bedford, MA 07130 Nadia Waheed 9 Kirk Street, Boston, MA 02132 Re:Change of Start Date Nadia: Reference is made to that certain Employment Agreement, by and between you and Ocular Therapeutix, Inc. made as of April 15, 2024. This letter confirms our agreement that the second sentence of the Employment Agreement shall be deleted and replaced by

Separation Agreement, by and between the Registrant and Rabia Gurses-Ozden, dated May 29, 2024

Exhibit 10.4 Execution Version VIA ELECTRONIC MAIL May 14, 2024 (as most recently revised on May 29, 2024) Dr. Rabia Gurses Ozden 1172 River Road Edgewater, NJ 07020 Dear Rabia: This letter agreement confirms our agreement with respect to your planned separation from employment with Ocular Therapeutix, Inc. (the “Company”). As we discussed, provided you sign and return this letter agreement to me

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00

Restated Certificate of Incorporation of the Registrant, as amended

Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF OCULAR THERAPEUTIX, INC. (originally incorporated on September 12, 2006) Ocular Therapeutix, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows: A. The current name of the Corpo

As filed with the Securities and Exchange Commission on June 17, 2024

As filed with the Securities and Exchange Commission on June 17, 2024 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Ocular Therapeutix, Inc.

Restated Certificate of Incorporation of the Registrant, as amended

Exhibit 4.1 RESTATED CERTIFICATE OF INCORPORATION OF OCULAR THERAPEUTIX, INC. (originally incorporated on September 12, 2006) Ocular Therapeutix, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows: A. The current name of the Corpo

Certificate of Amendment of Restated Certificate of Incorporation, as amended, of Ocular Therapeutix, Inc.

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF Ocular therapeutix, Inc. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Ocular Therapeutix, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware, does hereby certify as follows: A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 OCULAR THERAPEUTIX,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2024 OCULAR THERAPEUTIX, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 OCULAR THERAPEUTIX,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File Num

Amendment to Employment Agreement by and between the Registrant and Rabia Gurses-Ozden, dated as of March 14, 2024

Ocular Therapeutix FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment (the “First Amendment”) to the Agreement (as defined below) is dated as of March 13, 2024 (the “Effective Date”), and entered into by and between Ocular Therapeutix, Inc.

Amended and Restated License Agreement, dated January 27, 2012, between the Registrant and Incept LLC

CONFIDENTIAL TO INCEPT, LLC, AND OCULAR THERAPEUTIX, INC. Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. AMENDED AND RESTATED LICENSE AGREEMENT This AMENDED AND RESTATED LICENSE AGREEMENT (“Agreement”) is made and enter

As filed with the Securities and Exchange Commission on May 7, 2024

As filed with the Securities and Exchange Commission on May 7, 2024 Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

Ocular Therapeutix™ Reports First Quarter 2024 Results Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjec

Exhibit 99.1 Ocular Therapeutix™ Reports First Quarter 2024 Results Recent Leadership Appointments Put Ocular on Track to Become a Leader in Retinal Care Site Activation and Patient Enrollment for AXPAXLI™ SOL-1 Phase 3 wet AMD Trial Progressing with First Subjects Randomized in April 2024 Cash Expected to Support Operations Into 2028, Based on $482.9M March 31, 2024, Cash Balance June 13, 2024, I

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Ocular Therapeutix, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2024 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File N

OCULAR THERAPEUTIX, INC. Amendment No. 3 to 2019 Inducement Stock Incentive Plan

Exhibit 99.1 OCULAR THERAPEUTIX, INC. Amendment No. 3 to 2019 Inducement Stock Incentive Plan Ocular Therapeutix, Inc’s 2019 Inducement Stock Incentive Plan (the “Plan”), pursuant to Section 11(d) thereof, is hereby amended as set forth below. 1. The first sentence of Section 4(a) of the Plan be, and hereby is, deleted in its entirety and replaced with the following in lieu thereof: “Subject to ad

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 OCULAR THERAPEUTIX

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File N

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) OCULAR THERAPEUTIX, INC.

As filed with the Securities and Exchange Commission on March 25, 2024

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 25, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 OCULAR THERAPEUTIX

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File N

Employment Agreement, by and between the Registrant and Dr. Sanjay Nayak, dated as of February 21, 2024

EXECUTION COPY Exhibit 10.42 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) sets forth the terms and conditions of your employment with Ocular Therapeutix, Inc., and will be effective as of February 22, 2024 (the “Effective Date”). In consideration of the mutual covenants contained in this Agreement, the Company and Executive agree as follows: 1.Employment. The Company agrees to

Form of Restricted Stock Unit Agreement under 2021 Stock Incentive Plan

EXHIBIT 10.37 OCULAR THERAPEUTIX, INC. Restricted Stock Unit Agreement Ocular Therapeutix, Inc. (the “Company”) hereby grants the following restricted stock units pursuant to its 2021 Stock Incentive Plan, as amended. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the “Participant”): Grant Date: Number of restricted stock units (“RSUs”) granted:

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care Screening Underway in AXPAXLI™ Phase 3 SOL-1 Trial for Wet AMD Topline Clinical Data for AXPAXLI in Diabe

Exhibit 99.1 Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care Screening Underway in AXPAXLI™ Phase 3 SOL-1 Trial for Wet AMD Topline Clinical Data for AXPAXLI in Diabetic Retinopathy and PAXTRAVA™ in Glaucoma Expected in Q2 2024 Cash Expected to Support Operations Into At Least 2028 Based on $196M YE 20

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36554

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of Ocular Therapeutix, Inc. Jurisdiction of Incorporation or Organization Ocular Therapeutix Europe B.V. The Netherlands Ocular Therapeutix Securities Corp. The Commonwealth of Massachusetts

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Ocular Therapeutix, Inc.

Form of Restricted Stock Unit Agreement under 2019 Inducement Stock Incentive Plan

Exhibit 10.12 OCULAR THERAPEUTIX, INC. Restricted Stock Unit Agreement Ocular Therapeutix, Inc. (the “Company”) hereby grants the following restricted stock units pursuant to its 2019 Inducement Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the “Participant”): Grant Date: Number of restricted stock units (“RSUs”) granted:

As filed with the Securities and Exchange Commission on March 11, 2024

As filed with the Securities and Exchange Commission on March 11, 2024 Registration No.

Ocular Therapeutix, Inc. Compensation Recovery Policy

Exhibit 97.1 OCULAR THERAPEUTIX, INC. Compensation Recovery Policy This Compensation Recovery Policy (this “Policy”) is adopted by Ocular Therapeutix, Inc. (the “Company”) in accordance with Nasdaq Listing Rule 5608 (“Rule 5608”). This Policy is effective as of October 2, 2023 (the “Effective Date”). 1.Definitions (a)“Accounting Restatement” means a requirement that the Company prepare an accounti

OCUL / Ocular Therapeutix, Inc. / SUMMER ROAD LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* OCULAR THERAPEUTIX, INC. (Name of Issuer) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 67576A100 (CUSIP Number) Frank S. Vellucci, Esq. Norton Rose Fulbright US LLP 1301 Avenue of the Americas New York, NY 10019 (212) 408-5100

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Ocular Therapeutix, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2024 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission Fil

As filed with the Securities and Exchange Commission on February 22, 2024

As filed with the Securities and Exchange Commission on February 22, 2024 Registration No.

Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement

Exhibit 99.1 Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement BEDFORD, MA, February 22, 2024 (GLOBE NEWSWIRE) - Ocular Therapeutix, Inc. (Nasdaq:OCUL) (the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced

Amendment to Employment Agreement by and between the Registrant and Antony C. Mattessich, dated as of February 21, 2024

Exhibit 10.4 AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment (the “First Amendment”) to the Agreement (as defined below) is dated as of February 21, 2024 (the “Effective Date”), and entered into by and between Ocular Therapeutix, Inc., with offices at 24 Crosby Drive, Bedford, MA 01730 (hereinafter referred to as “Ocular” or the “Company”), and Antony C. Mattessich (hereinafter referred to

Employment Agreement, by and between the Registrant and Dr. Pravin U. Dugel, dated as of February 21, 2024

Exhibit 10.3 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) sets forth the terms and conditions of your employment with Ocular Therapeutix, Inc., and will be effective as of February 21, 2024 (the “Effective Date”). In consideration of the mutual covenants contained in this Agreement, the Company and Executive agree as follows: 1.            Employment. The Company agrees to empl

Form of Pre-Funded Warrant

Exhibit 4.1 Execution Version NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION (THE “SEC”) OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PU

Amendment No. 2 to 2019 Inducement Stock Incentive Plan

Exhibit 10.5 OCULAR THERAPEUTIX, INC. Amendment No. 2 to 2019 Inducement Stock Incentive Plan Ocular Therapeutix, Inc’s 2019 Inducement Stock Incentive Plan (the “Plan”), pursuant to Section 11(d) thereof, is hereby amended as set forth below. The first sentence of Section 4(a) of the Plan be, and hereby is, deleted in its entirety and replaced with the following in lieu thereof: “Subject to adjus

Registration Rights Agreement, dated as of February 21, 2024, by and among the Registrant and the other parties thereto

Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of February 21, 2024, by and among Ocular Therapeutix, Inc., a Delaware corporation (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of the date hereof (the “Purcha

Securities Purchase Agreement, dated February 21, 2024, by and among the Registrant and the other parties thereto

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of February 21, 2024 by and among Ocular Therapeutix, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). RECITALS A. The Company and the Investors are executing and de

OCUL / Ocular Therapeutix, Inc. / Opaleye Management Inc. Passive Investment

SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Ocular Therapeutix, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 67576A100 (CUSIP Number) James Silverman, One Boston Place, 26th Floor, Boston, MA 02108 (Name, Address and Telep

OCUL / Ocular Therapeutix, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Ocular Therapeutix Inc Title of Class of Securities: Common Stock CUSIP Number: 67576A100 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File

OCUL / Ocular Therapeutix, Inc. / Venrock Healthcare Capital Partners III, L.P. - SC 13G Passive Investment

SC 13G 1 tm2332531d2sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Ocular Therapeutix, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 67576A 10 0 (CUSIP Number) December 18, 2023 (Date of Event Which Requires Filing of this Statement) Ch

OCUL / Ocular Therapeutix, Inc. / Deep Track Capital, LP Passive Investment

SC 13G 1 deeptrack-ocul121423.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* OCULAR THERAPEUTIX, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 67576A100 (CUSIP Number) December 14, 2023 (Date of Event Which Requires Filing of this Statement) Check the

OCUL / Ocular Therapeutix, Inc. / SUMMER ROAD LLC - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* OCULAR THERAPEUTIX, INC. (Name of Issuer) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 67576A100 (CUSIP Number) Frank S. Vellucci, Esq. Norton Rose Fulbright US LLP 1301 Avenue of the Americas New York, NY 10019 (212) 408-5100

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2023 OCULAR THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2023 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission Fil

30,800,000 Shares Common Stock

TABLE OF CONTENTS  Filed Pursuant to Rule 424(b)(5)  Registration No. 333-275373 PROSPECTUS SUPPLEMENT (To Prospectus dated November 16, 2023) 30,800,000 Shares Common Stock We are offering 30,800,000 shares of our common stock, par value $0.0001 per share. Our common stock is listed on The Nasdaq Global Market under the symbol “OCUL.” On December 13, 2023, the closing price of our common stock, a

Underwriting Agreement, dated December 13, 2023, by and among Ocular Therapeutix, Inc. and Jefferies LLC, BofA Securities, Inc. and Piper Sandler & Co., as representatives of the several underwriters named therein

  Exhibit 1.1   30,800,000 Shares Ocular Therapeutix, Inc. UNDERWRITING AGREEMENT    December 13, 2023 JEFFERIES LLC BOFA SECURITIES, INC. PIPER SANDLER & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022   c/o BOFA SECURITIES, INC. One Bryant Park New York, New York 10036 c/o PIPER SANDLER & CO. 800 Nicollet Mall, Suite 800 Minneapoli

Ocular TherapeutixTM Announces Pricing of Public Offering of Common Stock

Exhibit 99.1 Ocular TherapeutixTM Announces Pricing of Public Offering of Common Stock BEDFORD, Mass, December 13, 2023 - Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the pricing of an underwritten public offering of

           Shares Common Stock

TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed.

Ocular Therapeutix, Inc. 24 Crosby Drive Bedford, MA 01730

Ocular Therapeutix, Inc. 24 Crosby Drive Bedford, MA 01730 November 14, 2023 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Ocular Therapeutix, Inc. Registration Statement on Form S-3 File No. 333-275373 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as ame

Form of Senior Note

Exhibit 4.5 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE

Amendment No. 1 to Employee Stock Purchase Plan, effective October 4, 2023

Exhibit 10.3 AMENDMENT NO. 1 TO 2014 EMPLOYEE STOCK PURCHASE PLAN OF OCULAR THERAPEUTIX, INC. The 2014 Employee Stock Purchase Plan (the “Plan”) of Ocular Therapeutix, Inc. (the “Company”) is hereby amended as follows (all capitalized terms used and not defined herein shall have the respective meanings ascribed to such terms in the Plan): 1. Clause (b) of Section 2 of the Plan is replaced in its e

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Ocular Therapeutix, Inc.

Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update FDA Agrees to Overall Design of the First Pivotal Trial for AXPAXLI in Wet AMD under a Special Protocol Assessment; Expect First Subject Dosed by Year-End Top-line

Exhibit 99.1 Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update FDA Agrees to Overall Design of the First Pivotal Trial for AXPAXLI in Wet AMD under a Special Protocol Assessment; Expect First Subject Dosed by Year-End Top-line Data from U.S.-based HELIOS Trial Evaluating AXPAXLI for Treatment of Non-Proliferative Diabetic Retinopathy Anticipated to be Presented

Amendment No. 1 to Senior Subordinated Convertible Note, dated as of August 2, 2023, between the Registrant and the holders thereof

Exhibit 10.2 Ocular Therapeutix, Inc. Amendment No. 1 to Senior Subordinated Convertible Note and Note Purchase Agreement August 2, 2023 WHEREAS Ocular Therapeutix, Inc., a Delaware corporation (the “Company”), issued a Senior Subordinated Convertible Note, dated March 1, 2019 (the “Note”), to Cap 1 LLC (the “Original Noteholder”), pursuant to a Note Purchase Agreement, dated as of February 21, 20

As filed with the Securities and Exchange Commission on November 7, 2023

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 7, 2023 Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File

Credit and Security Agreement, dated August 2, 2023, by and among Barings Finance LLC, as administrative agent, the Registrant, and the Lenders listed therein

Exhibit 10.1 CREDIT AND SECURITY AGREEMENT CREDIT AND SECURITY AGREEMENT (this “Agreement”), dated as of August 2, 2023 (the “Closing Date”) by and among Barings Finance LLC, a Delaware limited liability company (“Barings”), as administrative agent (“Agent”), the Lenders listed on the Credit Facility Schedule attached hereto and otherwise party hereto from time to time (each a “Lender”, and collec

Form of Subordinated Indenture

Exhibit 4.4 OCULAR THERAPEUTIX, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

Form of Subordinated Note

Exhibit 4.6 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE

Form of Senior Indenture

Exhibit 4.3 OCULAR THERAPEUTIX, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Inap

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2023 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File

Transformative Investigational Tyrosine Kinase Inhibitor Therapy for Retinal Vascular Diseases OCULAR THERAPEUTIX (NASDAQ: OCUL) Antony Mattessich President & Chief Executive Officer EURETINA Innovation Spotlight 4 th October 2023

Exhibit 99.1 Transformative Investigational Tyrosine Kinase Inhibitor Therapy for Retinal Vascular Diseases OCULAR THERAPEUTIX (NASDAQ: OCUL) Antony Mattessich President & Chief Executive Officer EURETINA Innovation Spotlight 4 th October 2023 2 Any statements in this presentation about future expectations, plans, and prospects for the Company, including the commercial iza tion of DEXTENZA® or any

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2023 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2023 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission Fi

2021 Stock Incentive Plan, as amended

Exhibit 10.2 Ocular Therapeutix, Inc. 2021 STOCK INCENTIVE PLAN, AS AMENDED 1. Purpose The purpose of this 2021 Stock Incentive Plan (the “Plan”) of Ocular Therapeutix, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to

Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update DEXTENZA® Net Product Revenue in Q2 2023 was $15.0 million, Representing Growth of Approximately 24% Over Q2 2022 Closed on a New $82.5 million Credit Facility; C

Exhibit 99.1 Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update DEXTENZA® Net Product Revenue in Q2 2023 was $15.0 million, Representing Growth of Approximately 24% Over Q2 2022 Closed on a New $82.5 million Credit Facility; Cash Runway Now Forecasted into 2025 First of Two Planned Pivotal Clinical Trials for OTX-TKI in Wet AMD Expected to Initiate in Q3 2023 C

As filed with the Securities and Exchange Commission on August 7, 2023

As filed with the Securities and Exchange Commission on August 7, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 OCULAR THERAPEUTIX

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File N

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Ocular Therapeutix, Inc.

Amendment No. 2 to Fourth Amended and Restated Credit and Security Agreement, dated May 4, 2023, by and among MidCap Financial Trust, as administrative agent, the Registrant, and the Lenders listed therein

Exhibit 10.1 Execution Version AMENDMENT NO. 2 TO FOURTH AMENDED AND RESTATED CREDIT and SECURITY AGREEMENT This AMENDMENT NO. 2 TO FOURTH AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of this 4th day of May, 2023, by and among OCULAR THERAPEUTIX, iNC., a Delaware corporation (the “Borrower”), MIDCAP FINANCIAL TRUST, as administrative agent for Lenders (in such c

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2023 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Third Amendment to Lease, by and between the Registrant and Cobalt PropCo 2020 LLC, dated June 30, 2023

Exhibit 10.1 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this “Amendment”) dated as of this 30th day of June, 2023 (the “Effective Date”), is entered into by and between COBALT PROPCO 2020, LLC, a Delaware limited liability company (“Landlord”), and OCULAR THERAPEUTIX, INC., a Delaware corporation, formerly known as I-Therapeutix, Inc. (“Tenant”). WITNESSETH: WHEREAS, Landlord (as succ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 OCULAR THERAPEUTIX,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 30, 2023 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 OCULAR THERAPEUTIX,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Month 10 Analysis (Presented at Angiogenesis 2023) Month 7 Analysis (Presented at AAO 2022) 1 OTX - TKI U.S. - based Wet AMD Clinical Trial Design OTX - TKI Arm Aflibercept Arm OTX - TKI 600µg single implant injection Aflibercept 2mg injection Sham i

Exhibit 99.1 Month 10 Analysis (Presented at Angiogenesis 2023) Month 7 Analysis (Presented at AAO 2022) 1 OTX - TKI U.S. - based Wet AMD Clinical Trial Design OTX - TKI Arm Aflibercept Arm OTX - TKI 600µg single implant injection Aflibercept 2mg injection Sham injection Study Visit Multicenter, Randomized, Double - masked Trial Screening Key Inclusion Criteria ▪ Sub foveal neovascularization seco

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2023 OCULAR THERAPEUTIX,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2023 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 OCULAR THERAPEUTIX, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

Ocular Therapeutix™ Provides First Quarter 2023 Financial Results and Corporate Update 12-month Top-Line Data from the U.S.-based Phase 1 Clinical Trial of OTX-TKI (axitinib intravitreal implant) for the Treatment of Wet AMD to be Presented in June a

Exhibit 99.1 Ocular Therapeutix™ Provides First Quarter 2023 Financial Results and Corporate Update 12-month Top-Line Data from the U.S.-based Phase 1 Clinical Trial of OTX-TKI (axitinib intravitreal implant) for the Treatment of Wet AMD to be Presented in June at the Clinical Trials at the Summit 2023 Meeting Presented Pre-Clinical and Clinical Data on Three Pipeline Programs at the 2023 Associat

Amendment No. 1 to Fourth Amended and Restated Credit and Security Agreement, dated March 31, 2023, by and among MidCap Financial Trust, as administrative agent, the Registrant, and the Lenders listed therein.

Exhibit 10.1 Execution Version AMENDMENT NO. 1 TO FOURTH AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT This AMENDMENT NO. 1 TO FOURTH AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (this “Agreement”) is made as of this 31st day of March, 2023, by and among OCULAR THERAPEUTIX, INC., a Delaware corporation (the “Borrower”), MIDCAP FINANCIAL TRUST, as administrative agent for Lenders (in suc

Ocular Therapeutix, Inc. 2021 Stock Incentive Plan, as amended, incorporated herein by reference to Appendix B to the Company’s definitive proxy statement, filed with the Securities and Exchange Commission on May 1, 2023.

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2023 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File N

Ocular Therapeutix™ Provides Fourth Quarter and Year-End 2022 Results and Corporate Update Presented Positive 10-month Interim Data from the U.S.-based Phase 1 Clinical Trial of OTX-TKI (axitinib intravitreal implant) for the Treatment of Wet AMD at

Exhibit 99.1 Ocular Therapeutix™ Provides Fourth Quarter and Year-End 2022 Results and Corporate Update Presented Positive 10-month Interim Data from the U.S.-based Phase 1 Clinical Trial of OTX-TKI (axitinib intravitreal implant) for the Treatment of Wet AMD at the Angiogenesis, Exudation, and Degeneration Annual 2023 Meeting Initiated Phase 1 Clinical Trial of OTX-TKI (axitinib intravitreal impl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36554

Consulting Agreement by and between the Registrant and Dr. Jeffrey Heier, dated as of October 17, 2022

Exhibit 10.43 HEALTHCARE PROFESSIONAL CONSULTANT AGREEMENT THIS HEALTHCARE PROFESSIONAL CONSULTANT AGREEMENT (this “Agreement”) is made and entered into as of October 17, 2022, by and between Ocular Therapeutix, Inc. (“Company”), a Delaware corporation having its principal place of business at 24 Crosby Dr., Bedford, MA 01730 USA and Heier Consulting, LLC, a Massachusetts LLC having its principal

As filed with the Securities and Exchange Commission on March 6, 2023

As filed with the Securities and Exchange Commission on March 6, 2023 Registration No.

Employment Agreement, by and between the Registrant and Christopher White, dated as of October 13, 2022

Exhibit 10.45 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) amends and restates the terms and conditions of your employment with Ocular Therapeutix, Inc., as set forth in your Employment Agreement dated July 9, 2019 (the “Existing Employment Agreement”), and will be effective as of October 13, 2022 (the “Effective Date”), provided that you remain employed by the Company as of th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 OCULAR THERAPEUTIX,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Ocular Therapeutix, Inc.

Employment Agreement, by and between the Registrant and Rabia Ozden-Gurses, dated as of September 28, 2022

EX-10.44 3 ocul-20221231xex10d44.htm EX-10.44 Exhibit 10.44 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) amends and restates the terms and conditions of your employment with Ocular Therapeutix, Inc., as set forth in your Employment Agreement dated November 30, 2020 (the “Existing Employment Agreement”), and will be effective as of September 28, 2022 (the “Effective Date”), prov

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of Ocular Therapeutix, Inc. Jurisdiction of Incorporation or Organization Ocular Therapeutix Europe B.V. The Netherlands Ocular Therapeutix Securities Corp. The Commonwealth of Massachusetts

OCUL / Ocular Therapeutix Inc / Opaleye Management Inc. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Ocular Therapeutix, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 67576A100 (CUSIP Number) James Silverman, One Boston Place, 26th Floor, Boston, MA 02108 (Name, Address and Telephone Number of Person Auth

OCUL / Ocular Therapeutix Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01558-oculartherapeutixinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Ocular Therapeutix Inc. Title of Class of Securities: Common Stock CUSIP Number: 67576A100 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to

Ocular Therapeutix™ Provides 2022 Year End Corporate Update and Reviews Expected 2023 Milestones Dextenza® Net Product Revenue in the Fourth Quarter of 2022 is Estimated to be $13.6 million, Growing Approximately 14% Over Previous Quarter and Approxi

EX-99.1 2 tm232417d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Ocular Therapeutix™ Provides 2022 Year End Corporate Update and Reviews Expected 2023 Milestones Dextenza® Net Product Revenue in the Fourth Quarter of 2022 is Estimated to be $13.6 million, Growing Approximately 14% Over Previous Quarter and Approximately 11% Over Same Quarter of Prior Year Dextenza Net Product Revenue for the Year Ending 2

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

Ocular Therapeutix™ Reports Third Quarter 2022 Financial Results and Business Update Announced Positive Interim Data from the U.S.-based Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD at the American Academy of Ophthalmology (AAO) 202

Exhibit 99.1 Ocular Therapeutix? Reports Third Quarter 2022 Financial Results and Business Update Announced Positive Interim Data from the U.S.-based Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting Initiation of OTX-TKI Phase 1 Clinical Trial for the treatment of Diabetic Retinopathy Planned for Q1 of 2023 and Phase

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2022 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission Fi

As filed with the Securities and Exchange Commission on August 8, 2022

As filed with the Securities and Exchange Commission on August 8, 2022 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File N

Consulting Agreement by and between the Registrant and Dr. Michael Goldstein, dated as of June 7, 2022

EXHIBIT 10.2 HEALTHCARE PROFESSIONAL CONSULTANT AGREEMENT THIS HEALTHCARE PROFESSIONAL CONSULTANT AGREEMENT (this ?Agreement?) for services is made and entered into as of June 7, 2022, by and between Ocular Therapeutix, Inc. (?Company?), a Delaware corporation having its principal place of business at 24 Crosby Dr., Bedford, MA 01730 USA, and Michael Goldstein, MD, MBA of 3 Hurlbut Street, Cambrid

Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results and Business Update Interim Data from the U.S.-based Clinical Trial for OTX-TKI for the Treatment of Wet AMD to be Presented at American Academy of Ophthalmology (AAO) in the Third Qua

Exhibit 99.1 Ocular Therapeutix? Reports Second Quarter 2022 Financial Results and Business Update Interim Data from the U.S.-based Clinical Trial for OTX-TKI for the Treatment of Wet AMD to be Presented at American Academy of Ophthalmology (AAO) in the Third Quarter of 2022 DEXTENZA? (dexamethasone ophthalmic insert) 0.4 mg Recorded Quarterly Net Product Revenue of $12.1 Million, Representing Yea

2021 Stock Incentive Plan, as amended

EXHIBIT 10.1 ? Ocular Therapeutix, Inc. 2021 STOCK INCENTIVE PLAN 1. Purpose The purpose of this 2021 Stock Incentive Plan (the ?Plan?) of Ocular Therapeutix, Inc., a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who are expected to make important contributions to the Compan

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Ocular Therapeutix, Inc.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2022 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File Num

Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg Recorded Quarterly Net Product Revenue of $12.5 Million, Representing Year-Over-Year Growth of 87% Guiding DEXTENZ

Exhibit 99.1 Ocular Therapeutix? Reports First Quarter 2022 Financial Results and Business Update DEXTENZA? (dexamethasone ophthalmic insert) 0.4 mg Recorded Quarterly Net Product Revenue of $12.5 Million, Representing Year-Over-Year Growth of 87% Guiding DEXTENZA Annual Net Product Revenue for 2022 between $55 to $60 million, Representing Annual Growth of Approximately 26% to 38% Expanding Commer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Ocular Therapeutix, Inc. 2021 Stock Incentive Plan, as amended, incorporated herein by reference to Appendix B to the Company’s definitive proxy statement, filed with the Securities and Exchange Commission on May 2, 2022

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission Fil

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of Ocular Therapeutix, Inc. ? ? ? ? Jurisdiction of Incorporation or Organization Ocular Therapeutix Europe B.V. ? The Netherlands Ocular Therapeutix Securities Corp. The Commonwealth of Massachusetts

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Post-Effective Amendment No 1 to Form S-3 (Form Type) Ocular Therapeutix, Inc.

As filed with the Securities and Exchange Commission on February 28, 2022

POS AM 1 tm227825d2posam.htm POS AM As filed with the Securities and Exchange Commission on February 28, 2022 Registration No. 333-251327 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OCULAR THERAPEUTIX, INC. (Exact name of registrant as specified in its charter) Delaware (S

As filed with the Securities and Exchange Commission on February 28, 2022

As filed with the Securities and Exchange Commission on February 28, 2022 Registration No.

Ocular Therapeutix™ Reports Fourth Quarter and Year-End 2021 Financial Results and Business Update DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg Recorded Net Quarterly Sales of $12.2 Million, Representing Year-Over-Year Growth of 77% Creating Ne

Exhibit 99.1 Ocular Therapeutix? Reports Fourth Quarter and Year-End 2021 Financial Results and Business Update DEXTENZA? (dexamethasone ophthalmic insert) 0.4 mg Recorded Net Quarterly Sales of $12.2 Million, Representing Year-Over-Year Growth of 77% Creating New Business Unit Focused on Optimizing the Commercial Opportunity for DEXTENZA in the Office Setting Completed Enrollment in U.S.-based Cl

Form of Option Grant Agreement under 2021 Stock Incentive Plan

Exhibit 10.39 ? OCULAR THERAPEUTIX, INC. STOCK OPTION AGREEMENT ? Ocular Therapeutix, Inc. (the ?Company?) hereby grants the following stock option pursuant to its 2021 Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant ? ? Name of optionee (the ?Participant?): ? Grant Date: ? Incentive Stock Option or Nonstatutory Stock Option: ? Number of share

As filed with the Securities and Exchange Commission on February 28, 2022

As filed with the Securities and Exchange Commission on February 28, 2022 Registration No.

Description of Securities Registered under Section 12 of the Exchange Act

Exhibit 4.3 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT The following description of registered securities of Ocular Therapeutix, Inc. is intended as a summary only and therefore is not a complete description. The following description is qualified by reference to our certificate of incorporation, which we refer to as our Certificate of Incorporation; our by-laws, whi

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Ocular Therapeutix, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

Table of Contents ? ? ? ? ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

Power of Attorney for Merilee Raines, dated February 26, 2022

Exhibit 24.2 POWER OF ATTORNEY I, the undersigned director of Ocular Therapeutix Inc., hereby severally constitute and appoint Antony Mattessich and Donald Notman, and each of them singly, my true and lawful attorneys-in-fact and agents, with full power to any of them, and to each of them singly, to sign for me and in my name in the capacity indicated below Post-Effective Amendment No. 1 to the Re

Amendment No. 1 to License Agreement, by and between the Registrant and AffaMed Therapeutics (HK) Limited, dated as of October 28, 2021

Exhibit 10.41 ? AMENDMENT NO. 1 TO LICENSE AGREEMENT ? This Amendment No. 1 to License Agreement (this ?Amendment?) by and between Ocular Therapeutix, Inc., a corporation organized and existing under the laws of Delaware with a principal place of business at 24 Crosby Drive, Bedford, MA 01730 (?Ocular?), and Affamed Therapeutics (HK) Limited, a corporation duly organized and existing under the law

Form of Restricted Stock Unit Agreement under 2021 Stock Incentive Plan

Exhibit 10.40 ? OCULAR THERAPEUTIX, INC. ? RESTRICTED STOCK UNIT AGREEMENT Ocular Therapeutix, Inc. (the ?Company?) hereby grants the following restricted stock units pursuant to its 2021 Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof. ? Notice of Grant ? Name of recipient (the ?Participant?): ? Grant Date: ? Number of restricted stock units (?RSUs?) granted:

OCUL / Ocular Therapeutix Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SC 13G 1 tv01558-oculartherapeutixinc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Ocular Therapeutix Inc. Title of Class of Securities: Common Stock CUSIP Number: 67576A100 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule purs

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2022 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File

OCUL / Ocular Therapeutix Inc / Opaleye Management Inc. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Ocular Therapeutix, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 67576A100 (CUSIP Number) James Silverman, One Boston Place, 26th Floor, Boston, MA 02108 (Name, Address and Telephone Number of Person Au

Ocular Therapeutix™ Reports Third Quarter 2021 Financial Results and Business Update DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg Recorded Net Quarterly Sales of $11.9 Million, Representing Year-Over-Year Growth of 120% FDA Approved Supplementa

Exhibit 99.1 Ocular Therapeutix? Reports Third Quarter 2021 Financial Results and Business Update DEXTENZA? (dexamethasone ophthalmic insert) 0.4 mg Recorded Net Quarterly Sales of $11.9 Million, Representing Year-Over-Year Growth of 120% FDA Approved Supplemental New Drug Application (sNDA) for DEXTENZA for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis DEXTENZA Will Be P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2021 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2021 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission Fi

Ocular Therapeutix™ Reports Second Quarter 2021 Financial Results and Business Update DEXTENZA® Recorded Net Quarterly Sales of $11.1 Million, Representing Quarterly Sequential Growth of Approximately 65% Initiated First Clinical Trial in the U.S. to

Exhibit 99.1 Ocular Therapeutix? Reports Second Quarter 2021 Financial Results and Business Update DEXTENZA? Recorded Net Quarterly Sales of $11.1 Million, Representing Quarterly Sequential Growth of Approximately 65% Initiated First Clinical Trial in the U.S. to Assess a Single OTX-TKI Implant Containing a 600?g Dose of Axitinib for the Treatment of Wet Age-Related Macular Degeneration Conference

Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant

Exhibit 5.9 +1 212 230-8800 (t) +1 212 230 8888 (f) wilmerhale.com August 9, 2021 Ocular Therapeutix, Inc. 24 Crosby Drive Bedford, MA 01730 Re: Post-Effective Amendments to Registration Statement on Form S-8 for Shares of Common Stock, par value $0.0001 per share, of Ocular Therapeutix, Inc. Ladies and Gentlemen: We have assisted in the preparation of a Post-Effective Amendment No. 1 to Registrat

Post-Effective Amendment No. 1 to Form S-8 Registration Statements relating to such Form S-8 Registration Statement, filed with the Securities and Exchange Commission on August 9, 2021

As filed with the Securities and Exchange Commission on August 9, 2021 Registration No.

Registration Statement on Form S-8, File No. 333-258642, filed with the Securities and Exchange Commission on August 9, 2021

As filed with the Securities and Exchange Commission on August 9, 2021 Registration No.

As filed with the Securities and Exchange Commission on August 9, 2021

As filed with the Securities and Exchange Commission on August 9, 2021 Registration No.

Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant

Exhibit 5.9 +1 212 230-8800 (t) +1 212 230 8888 (f) wilmerhale.com August 9, 2021 Ocular Therapeutix, Inc. 24 Crosby Drive Bedford, MA 01730 Re: Post-Effective Amendments to Registration Statement on Form S-8 for Shares of Common Stock, par value $0.0001 per share, of Ocular Therapeutix, Inc. Ladies and Gentlemen: We have assisted in the preparation of a Post-Effective Amendment No. 1 to Registrat

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File N

Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant

Exhibit 5.9 +1 212 230-8800 (t) +1 212 230 8888 (f) wilmerhale.com August 9, 2021 Ocular Therapeutix, Inc. 24 Crosby Drive Bedford, MA 01730 Re: Post-Effective Amendments to Registration Statement on Form S-8 for Shares of Common Stock, par value $0.0001 per share, of Ocular Therapeutix, Inc. Ladies and Gentlemen: We have assisted in the preparation of a Post-Effective Amendment No. 1 to Registrat

Open Market Sale Agreement, dated as of August 9, 2021, by and between the Registrant and Jefferies LLC

EX-1.1 2 tm2124481d2ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 EXECUTION VERSION OCULAR THERAPEUTIX, INC. Shares of Common Stock (par value $0.0001 per share) Open Market Sale AgreementSM August 9, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Ocular Therapeutix, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Jefferies LLC

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File N

Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant

Exhibit 5.9 +1 212 230-8800 (t) +1 212 230 8888 (f) wilmerhale.com August 9, 2021 Ocular Therapeutix, Inc. 24 Crosby Drive Bedford, MA 01730 Re: Post-Effective Amendments to Registration Statement on Form S-8 for Shares of Common Stock, par value $0.0001 per share, of Ocular Therapeutix, Inc. Ladies and Gentlemen: We have assisted in the preparation of a Post-Effective Amendment No. 1 to Registrat

As filed with the Securities and Exchange Commission on August 9, 2021

As filed with the Securities and Exchange Commission on August 9, 2021 Registration No.

As filed with the Securities and Exchange Commission on August 9, 2021

As filed with the Securities and Exchange Commission on August 9, 2021 Registration No.

Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant

Exhibit 5.9 +1 212 230-8800 (t) +1 212 230 8888 (f) wilmerhale.com August 9, 2021 Ocular Therapeutix, Inc. 24 Crosby Drive Bedford, MA 01730 Re: Post-Effective Amendments to Registration Statement on Form S-8 for Shares of Common Stock, par value $0.0001 per share, of Ocular Therapeutix, Inc. Ladies and Gentlemen: We have assisted in the preparation of a Post-Effective Amendment No. 1 to Registrat

As filed with the Securities and Exchange Commission on August 9, 2021

As filed with the Securities and Exchange Commission on August 9, 2021 Registration No.

Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant

Exhibit 5.9 +1 212 230-8800 (t) +1 212 230 8888 (f) wilmerhale.com August 9, 2021 Ocular Therapeutix, Inc. 24 Crosby Drive Bedford, MA 01730 Re: Post-Effective Amendments to Registration Statement on Form S-8 for Shares of Common Stock, par value $0.0001 per share, of Ocular Therapeutix, Inc. Ladies and Gentlemen: We have assisted in the preparation of a Post-Effective Amendment No. 1 to Registrat

Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant

Exhibit 5.9 +1 212 230-8800 (t) +1 212 230 8888 (f) wilmerhale.com August 9, 2021 Ocular Therapeutix, Inc. 24 Crosby Drive Bedford, MA 01730 Re: Post-Effective Amendments to Registration Statement on Form S-8 for Shares of Common Stock, par value $0.0001 per share, of Ocular Therapeutix, Inc. Ladies and Gentlemen: We have assisted in the preparation of a Post-Effective Amendment No. 1 to Registrat

Restated Certificate of Incorporation of the Registrant, as amended

? Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF OCULAR THERAPEUTIX, INC. (originally incorporated on September 12, 2006) Ocular Therapeutix, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), does hereby certify as follows: A. The current name of the Cor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

As filed with the Securities and Exchange Commission on August 9, 2021

As filed with the Securities and Exchange Commission on August 9, 2021 Registration No.

Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant

Exhibit 5.9 +1 212 230-8800 (t) +1 212 230 8888 (f) wilmerhale.com August 9, 2021 Ocular Therapeutix, Inc. 24 Crosby Drive Bedford, MA 01730 Re: Post-Effective Amendments to Registration Statement on Form S-8 for Shares of Common Stock, par value $0.0001 per share, of Ocular Therapeutix, Inc. Ladies and Gentlemen: We have assisted in the preparation of a Post-Effective Amendment No. 1 to Registrat

CALCULATION OF REGISTRATION FEE

TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-251327? CALCULATION OF REGISTRATION FEE ? ? Title of Each Class of Securities to be Registered ? ? ? Proposed Maximum Aggregate Offering Price ? ? ? Amount of Registration Fee(1) ? Common Stock, par value $0.0001 per share ? ? ? $100,000,000 ? ? ? $10,910.00 ? ? (1) Calculated in accordance with Rule 457(o) under the Securitie

As filed with the Securities and Exchange Commission on August 9, 2021

As filed with the Securities and Exchange Commission on August 9, 2021 Registration No.

As filed with the Securities and Exchange Commission on August 9, 2021

As filed with the Securities and Exchange Commission on August 9, 2021 Registration No.

Ocular Therapeutix™ Announces Second Quarter 2021 Preliminary Net Product Revenue of $11.7 Million Company Anticipates Record Quarter for In-Market DEXTENZA Sales Second Quarter 2021 Net Product Revenue Up Approximately 60% and In-Market Unit Volumes

Exhibit 99.1 Ocular Therapeutix? Announces Second Quarter 2021 Preliminary Net Product Revenue of $11.7 Million Company Anticipates Record Quarter for In-Market DEXTENZA Sales Second Quarter 2021 Net Product Revenue Up Approximately 60% and In-Market Unit Volumes Up Approximately 50% Sequentially Over the First Quarter of 2021 BEDFORD, Mass.-(BUSINESS WIRE)? July 22, 2021 - Ocular Therapeutix, Inc

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2021 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2021 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File Nu

3.1 Certificate of Amendment of Restated Certificate of Incorporation of Ocular Therapeutix, Inc.

Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF Ocular therapeutix, Inc. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Ocular Therapeutix, Inc. (the ?Corporation?), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware, does hereby certify as follows: A

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2021 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File Num

Fourth Amended and Restated Credit and Security Agreement dated June 4, 2021 by and among MidCap Financial Trust, as administrative agent, Ocular Therapeutix, Inc., and the Lenders listed therein

Exhibit 10.1 Execution Version FOURTH AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT THIS FOURTH AMENDED AND RESTATED CREDIT AND SECURITY AGREEMENT (this ?Agreement?), dated as of June 4, 2021 (the ?Closing Date?) by and among MIDCAP FINANCIAL TRUST, a Delaware statutory trust (?MidCap?), as administrative agent (together with its successors and assigns, ?Agent?), the Lenders listed on the Cre

Quarterly Report - 10-Q

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Ocular Therapeutix™ Reports First Quarter 2021 Financial Results and Business Update DEXTENZA® Achieved Quarterly Record of 16,634 Billable Units Sold to End Customers, Representing Quarterly Sequential Growth of 15%.

Exhibit 99.1 Ocular Therapeutix? Reports First Quarter 2021 Financial Results and Business Update DEXTENZA? Achieved Quarterly Record of 16,634 Billable Units Sold to End Customers, Representing Quarterly Sequential Growth of 15%. BEDFORD, Mass.-(BUSINESS WIRE)? May 5, 2021 - Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercial

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2021 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File N

- DEFA14A

? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Pro

2021 Stock Incentive Plan

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2021 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File N

- PRE 14A

Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of Ocular Therapeutix, Inc. ? Jurisdiction of Incorporation or Organization Ocular Therapeutix Europe B.V. ? The Netherlands ?

Amendment to 2019 Inducement Stock Incentive Plan

Exhibit 10.9 OCULAR THERAPEUTIX, INC. Amendment to 2019 Inducement Stock Incentive Plan ? Ocular Therapeutix, Inc?s 2019 Inducement Stock Incentive Plan (the ?Plan?), pursuant to Section 11(d) thereof, is hereby amended as set forth below. ? The first sentence of Section 4(a) of the Plan be, and hereby is, deleted in its entirety and replaced with the following in lieu thereof: ?Subject to adjustm

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2021 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File N

Employment Agreement, by and between the Registrant and Philip Strassburger, dated August 28, 2020

Exhibit 10.19 ? Execution Copy ? EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the ?Agreement?) is made on August 28, 2020, by and between Ocular Therapeutix, Inc., a Delaware corporation (the ?Company?), and Philip C. Strassburger (?Executive?) and the employment relationship between the Company and the Executive shall be governed by this Agreement commencing as of the Effective Date (as define

Ocular Therapeutix™ Reports Fourth Quarter and Year End 2020 Financial Results and Business Update

Exhibit 99.1 Ocular Therapeutix? Reports Fourth Quarter and Year End 2020 Financial Results and Business Update BEDFORD, Mass.-(BUSINESS WIRE)? March 11, 2021 - Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the fou

Supplement to License Agreement, by and between the Registrant and AffaMed Therapeutics Limited, dated as of January 18, 2021

Exhibit 10.36 ? SUPPLEMENT ? This Supplement (this ?Supplement?) to License Agreement by and between Ocular Therapeutix, Inc. and Affamed Therapeutics Limited is made and entered into as of January 18, 2021. ? WHEREAS, Ocular Therapeutix, Inc. (?Ocular?) and Affamed Therapeutics Limited (?Affamed?) entered into a License Agreement dated as of October 28, 2020 (the ?License Agreement?); and ? WHERE

Annual Report - 10-K

Table of Contents ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

Form S-8, File No. 333-254143, filed with the Securities and Exchange Commission on March 11, 2021

As filed with the Securities and Exchange Commission on March 11, 2021 Registration No.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2021 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2) OCULAR THERAPEUTIX, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2) OCULAR THERAPEUTIX, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 67576A100 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate

Cohort 1: n=6 until Month 9; Cohort 2: n=7 until Month 9; n=6 for Month 11; n=6 for Month 12; n=4 for Month 14 Cohort 3a: n=5 until Month 1; n=3 for Month 2; n=2 for Month 3; n=1 for Month 4.5 & 6; Cohort 3b: n=2 until Month 2; n=1 unti l M onth 3 *A

EX-99.1 2 tm216360d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cohort 1: n=6 until Month 9; Cohort 2: n=7 until Month 9; n=6 for Month 11; n=6 for Month 12; n=4 for Month 14 Cohort 3a: n=5 until Month 1; n=3 for Month 2; n=2 for Month 3; n=1 for Month 4.5 & 6; Cohort 3b: n=2 until Month 2; n=1 unti l M onth 3 *All BCVA and CSFT values compared to Baseline visit; NOTE: Interim review, unmonitored data; D

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2021 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File

OTX - TIC, AN INTRACAMERAL HYDROGEL - BASED TRAVOPROST IMPLANT TO TREAT PATIENTS WITH GLAUCOMA & OCULAR HYPERTENSION PHASE 1 TRIAL UPDATE MICHAEL GOLDSTEIN, MD, MBA PRESIDENT, OPHTHALMOLOGY & CHIEF MEDICAL OFFICER GLAUCOMA 360 | VIRTUAL | JANUARY , 2

Exhibit 99.1 OTX - TIC, AN INTRACAMERAL HYDROGEL - BASED TRAVOPROST IMPLANT TO TREAT PATIENTS WITH GLAUCOMA & OCULAR HYPERTENSION PHASE 1 TRIAL UPDATE MICHAEL GOLDSTEIN, MD, MBA PRESIDENT, OPHTHALMOLOGY & CHIEF MEDICAL OFFICER GLAUCOMA 360 | VIRTUAL | JANUARY , 2021 (NASDAQ: OCUL) FINANCIAL DISCLOSURE Sponsorship for the clinical trial: Ocular Therapeutix, Inc. The author(s) do have financial inte

TRANSFORMING DRUG DELIVERY LEVERAGING A NOVEL TECHNOLOGY PLATFORM (NASDAQ: OCUL) ANTONY MATTESSICH, CHIEF EXECUTIVE OFFICER January 2021

Exhibit 99.1 TRANSFORMING DRUG DELIVERY LEVERAGING A NOVEL TECHNOLOGY PLATFORM (NASDAQ: OCUL) ANTONY MATTESSICH, CHIEF EXECUTIVE OFFICER January 2021 FORWARD LOOKING STATEMENTS 2 Any statements in this presentation about future expectations, plans, and prospects for the Company, including the commercialization of DEXTENZA®, ReSure ® Sealant, or any of the Company’s product candidates ; the commerc

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2021 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission File

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2020 OCULAR THERAPEUTIX, INC. (Exact Name of Company as Specified in Charter) Delaware 001-36554 20-5560161 (State or Other Jurisdiction of Incorporation) (Commission Fil